Life Science News

Dr. Peter W. Vaughan, CM, CD, MA, MD, MPH, ICD.D, Chairman of the Board of Directors at WellteQ Digital Health Inc. has been appointed to the Order of Canada.Recognised by the Governor General of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health"Digital Health market size projected at nearly 25% CAGR from 2019 to ...
  • Dr. Peter W. Vaughan, CM, CD, MA, MD, MPH, ICD.D, Chairman of the Board of Directors at WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) has been appointed to the Order of Canada.
  • Recognised by the Governor General of Canada "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health"
  • Digital Health market size projected at nearly 25% CAGR from 2019 to become a US$660 billion industry by 2025 (Statistica Research - July 2021)

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCBB: WTEQF), (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce the Company's Chairman, Dr Peter Vaughan, has been appointed to the Order of Canada by the Governor General of Canada.

The Governor General cited the appointment of Dr Vaughan "for his contributions to Canada's health care system, and for his pioneering leadership in the establishment and advancement of digital health".

In 2019, the global digital health market was worth an estimated 175 billion U.S. dollars. With an expected CAGR of almost 25 percent from 2019 to 2025, the digital health market should reach nearly US$660 billion by 2025, according to Statistica Research, 26 July 20211.

Dr Vaughan, who's career spans medicine, public healthcare, academia and multiple Board and Executive positions is recognized for his tenacious evangelism of healthcare modernization. Dr Vaughan was appointed Chairman of the Board of Directors for Wellteq just prior to the Company's listing on the Canadian Securities Exchange (CSE) in March 2021 and continues to lead the Company's execution to modernize healthcare delivery through the deployment of the Wellteq platform.

For more information about the Order of Canada, the Governor General of Canada or the other appointees refer to the website of The Governor General of Canada2.

1 https://www.statista.com/statistics/1092869/global-digital-health-market-size-forecast/

2 https://www.gg.ca/en/activities/2021/governor-general-announces-135-new-appointments-order-canada

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading global provider of personalized digital health and wellness solutions across the continuum of care. To learn more, visit http://www.wellteq.co.

Download the Wellteq Corporate Presentation:
https://wellteq.co/about/investors/

Wellteq Investor Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109660

News Provided by Newsfile via QuoteMedia

WTEQ:CC
WellteQ Digital Health

WellteQ Digital Health

Overview

In 2020, the COVID-19 global pandemic shook traditional healthcare structures on a worldwide level. Not only did healthcare institutions need integrated systems to manage the influx of patients and personalized information, but companies needed to keep track of the wellness of their teams as large numbers of employees switched to remote work environments.

In this increasingly digital age, the sphere of telemedicine helped to not only revolutionize healthcare navigation but our perception of wellness management. Telemedicine has proven that the world could use innovative digital technologies to not only manage health complications but potentially proactively prevent them. As the global healthcare market is forecasted to grow to nearly US$11.9 trillion by 2022, investing in wellness technology today is investing in the healthcare of tomorrow.

WellteQ Digital Health (CSE:WTEQ) (OTCQB:WTEQF) is a digitally driven health and wellness company aiding the transition from old school healthcare navigation to a more personalized data-driven patient experience. Through data capture, artificial intelligence and analytics solutions, the company seeks to help people take control of their own wellness and overcome accessibility issues around health.

Keep reading... Show less
continuum global solutions

Wellteq Digital Health Inc. Upcoming Investor Events

  • WellteQ Digital Health Inc. (CSE: WTEQ / OTCQB: WTEQF) is pleased to announce two upcoming investor events.
  • Wellteq will be hosting an Investor Webcast on November 10 th , 2021.
  • Wellteq will also be participating in the 3 rd Annual Canaccord Genuity Health & Wellness Conference on November 16 th , 2021

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) , (the "Company" or "Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce two upcoming investor events.

Wellteq Investor Webcast on Wednesday, November 10th, 2021

Keep reading... Show less
"investingnews.com"

Wellteq Digital Health Inc. Partners With Top Global University to Commercialise Sleep Research

  • WellteQ Digital Health Inc. (CSE: WTEQ / OTCQB: WTEQF) has signed a Letter of Intent (LOI) to commercialise sleep technology developed by Monash University, Australia to combat fatigue, insomnia, and burnout in shift worker employees.
  • Global Sleep Market Size to Reach Revenues of USD 137.16 Billion by 2026 1
  • Wellteq intends to integrate this intellectual property (IP) along with its recently announced licensed sleep technology into the Company's existing health assessment and coaching capabilities and create a market leading sleep and fatigue solution for employers and insurers globally.
  • Commercialisation efforts will initially focus on the aviation, healthcare, mining and construction sectors where workers are at heightened risk of excessive sleepiness at work and insomnia at home.
  • Monash University is a globally recognised university in Melbourne, Australia, which has researched and developed sleep IP for over seven-years and holds a patent application for this program.

WellteQ Digital Health Inc. (CSE: WTEQ) (OTCQB: WTEQF) , (the "Company" or Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce an executed letter of intent for a Strategic Partnership to commercialize research and intellectual property for sleep assessment and coaching solutions with Monash University, Australia.

Monash University's Turner Institute for Brain and Mental Health, Deputy Director Professor Shantha Rajaratnam said: "We are delighted to explore a partnership with Wellteq, a company committed to improving health and wellbeing through digital solutions. We will work with Wellteq to deliver sleep-related products for improving workplace mental health and wellbeing, and also productivity."

Keep reading... Show less
asia pacific wearable medical device

Wellteq Digital Health Inc. Acquires Perpetual License for Digital Sleep Tech IP

  • WellteQ Digital Health Inc. (CSE: WTEQ, OTCQB: WTEQF) increases its investment into sleep solution capabilities, as one of its four behavioural levers of health coaching.
  • Wellteq has signed a perpetual license agreement for sleep chronotype assessments and education content from one of Asia Pacific's leading sleep technology companies.
  • Wellteq intends to promptly integrate newly licensed sleep assets into the existing corporate health solution and accelerate development of clinical sleep solutions.
  • Initial transaction terms have been adjusted downward from AU$600,000 to CA$70,000 to reflect the unrestricted perpetual license versus an acquisition.
  • This license accelerates Wellteq's sleep assessment and coaching capabilities by an estimated 12 months.
  • Sleep market revenues are accelerating and projected to reach US$137.16 billion by 2026 which would exceed the current market for corporate wellness by 100%.

WellteQ Digital Health Inc. (CSE:WTEQ) (OTCBB:WTEQF) , (the "Company" or Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce, that further to the Company's News Release of June 8 th 2021, Wellteq has completed the execution of a perpetual license agreement for sleep chronotype assessments and educational content from with one of Asia Pacific's leading sleep technology providers. Under the perpetual license, Wellteq has unrestricted usage rights in relation to the assets of the license.

Wellteq focuses on coaching its subscribers within the four levers of behavioural health activity, nutrition, mindset, and sleep. The Company recognises the existing importance of sleep within established occupational Health and Safety divisions of industries where fatigue-related accidents can cause serious injury, fatality, and significant direct and liability costs. Industries such as aviation, logistics, mining, construction, and oil and gas have had dedicated divisions to combat this risk for decades. Wearables such as Apple Watch (NASDAQ: AAPL), Fitbit (NASDAQ: GOOG) and Garmin (NASDAQ: GRMN) and data driven health providers such as Wellteq are rapidly advancing solution capabilities for these traditional enterprise customers and for a new generation of customers in the insurance and healthcare sectors.

Keep reading... Show less
grmn stock

Wellteq Digital Health Inc. Extends Private Health Insurer Partnership For 3-Years

  • WellteQ Digital Health Inc. (CSE:WTEQ, OTCQB:WTEQF) has extended its agreement with Australia's fourth largest private health insurer through a three-year Service Agreement.
  • nib health funds (NHF:ASX), are enhancing member engagement by offering a customised Wellteq platform to their members.
  • nib has been Wellteq's largest corporate customer for over two years and this new 3-year Service Agreement is an extension of that successful relationship.
  • Wellteq's digital health solution integrates its preferred partners such as Garmin and other health provider partners into the nib-customised digital wellness app and delivers health coaching, gamification, rewards and other features to nib's members.

WellteQ Digital Health Inc. (CSE:WTEQ) (OTCBB:WTEQF) , (the "Company" or Wellteq"), which supplies digital health and wellness solutions to customers in 12 languages across 30 countries is pleased to announce a three-year contract extension with the Company's largest client, nib health funds (ASX:NHF) based in Australia.

nib is Australia's fourth-largest private health insurer and provides private health insurance coverage to over 1.2 million policyholders across Australia. In line with the health insurer's Payer to Partner journey, nib is focused on providing greater access to personalised treatment and care for its members as it moves away from being a traditional payer of claims and towards its ambition of becoming a health partner.

Keep reading... Show less
"biotech" seo or ppc or sem or "digital marketing" -movie -theater

Wellteq Digital Health Inc. Corporate Update Shows Strong Growth

  • SaaS revenue growth +100% for the year ended June 30, 2021 (unaudited).
  • User growth exceeds 100% for the calendar year to date.
  • Growing client base of multi-national corporate institutions.
  • New corporate partnerships to accelerate premium SaaS revenue streams.
  • Continued investment in expanding the team and technology.
  • Strong treasury with CA$7.15m cash reserves (August 31, 2021).

WellteQ Digital Health Inc. (CSE:WTEQ) (OTCQB:WTEQF) (the "Company" or "Wellteq"), a leading global provider of digital health and wellness solutions, is pleased to provide the following corporate update.

Digital Health SaaS Revenue Growth and User Growth

Keep reading... Show less
BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

  • 2022 Revenue will include sales of VINIA® and Cannabis, both with high gross margins
  • Major investments in the BioFarming platform and Intellectual property
  • New patent application covers a 700% increase in Bioreactor production output

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") announces that following the successful over-delivery of revenue targets versus guidance provided in 2021, the Company is estimating 2022 revenue to be between USD $5M-$7M, representing a significant growth of 2.5X-3.5X over 2021. The range in guidance is due to two primary determinants; the speed in which the biological technology transfer to its new 20 Tonyear facility is completed, and regulatory timelines influencing the conversion of the existing 2 Tonsyear facility from VINIA to the production of Cannabis.

The Company is also projecting to achieve break-even cash flow in 2023, when the business reaches its first scaling point. For 2022, BioHarvest plans to continue to invest heavily in R&D (as a percentage of total revenue) and in the building of manufacturing capacity for its Cannabis vertical in Israel and abroad.

Keep reading... Show less

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

-- Enrolled Patients in These Studies May Continue Receiving Study Medicine --

-- Studies Outside of Combination with Azacitidine Unaffected --

Keep reading... Show less
Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it will soon be available for order online throughout the United States through GTFO It's Vegan, a progressive online vegan market serving consumers across the U.S

Komo received a purchase order from GTFO and plans to ship its first pallet of Komo plant-based comfort foods to GTFO headquarters in California this week. Consumers across the United States will soon be able to order, for home delivery, all of Komo's frozen products online at GTFO It's Vegan.

Keep reading... Show less
George Ragogna Appointed CFO

George Ragogna Appointed CFO

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce that Mr. George Ragogna has been appointed Chief Financial Officer (CFO), replacing current Chief Financial Officer (CFO), Mr. Bryan Carson

Mr. Ragogna has over 30 years of experience in the Canadian financial services industry with over 20 years in a progressive leadership role specializing in; strategic planning, corporate sales, workforce optimization and regulatory compliance for the Co-operators Group Limited, a leading Canadian multi-line insurance and financial services co-operative with $56.4 billion in assets under management.

Keep reading... Show less

Allergan Aesthetics Announces Open Casting Call for BOTOX® Cosmetic

Allergan Aesthetics, an ABBVie company (NYSE: ABBV) announced today it will be hosting an open casting call seeking people who would like to share their BOTOX ® Cosmetic Story. The company continues its commitment to showcase real people and real stories as part of its larger mission to create a more inclusive and authentic dialogue around the decision to receive aesthetic treatments. Building on the success of the original ' See Yourself ' campaign launched in 2021, BOTOX ® Cosmetic, is launching its first ever open-casting call which will bring together new and existing patients to share their personal stories and treatment journeys in a national advertising campaign.

"We continue to be inspired by the individuals who use our products. We know that everyone has their own unique reason for receiving BOTOX ® Cosmetic, and we want those authentic faces and voices to be a part of our campaign," said Carrie Strom , President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "Our goal is for people to see others like them and be empowered by their lives and their decisions. 'See Yourself' demystifies treatment, encourages transparency, and reflects our consumers in all of their beautiful forms, genders, and colors."

Keep reading... Show less

FDA Approves Veklury® for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

-- Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo --

-- NIH Guidelines Recommend Veklury for the Treatment of Non-Hospitalized Patients at High Risk --

Keep reading... Show less

Latest Press Releases

Related News

×